AKI involves early Toll-like receptor (TLR)-driven immunopathology, and resolution of inflammation is needed for rapid regeneration of injured tubule cells. Notably, activation of TLRs also has been implicated in epithelial repair. We hypothesized that TLR signaling drives tubule regeneration after acute injury through the induction of certain ILs. Systematic screening in vitro identified IL-22 as a candidate proregeneratory factor in primary tubular cell recovery, and IL-22 deficiency or IL-22 blockade impaired postischemic tubular recovery after AKI in mice. Interstitial mononuclear cells, such as dendritic cells and macrophages, were the predominant source of IL-22 secretion, whereas IL-22 receptor was expressed by tubular epithelial cells exclusively. Depleting IL-22-producing cells during the healing phase impaired epithelial recovery, which could be rescued entirely by reconstituting mice with IL-22. In vitro, necrotic tubular cells and oxidative stress induced IL-22 secretion selectively through TLR4. Although TLR4 blockade during the early injury phase prevented tubular necrosis and AKI, TLR4 blockade during the healing phase suppressed IL-22 production and impaired kidney regeneration. Taken together, these results suggest that necrotic cell-derived TLR4 agonists activate intrarenal mononuclear cells to secrete IL-22, which accelerates tubular regeneration and recovery in AKI.
AKI involves a sterile inflammatory response that contributes to the extent of tubular cell damage. 1 In turn, tubular cell necrosis is the predominant trigger for this associated inflammatory response, because dying cells release intracellular molecules, such as HMGB1, histones, uric acid, or ATP, that elicit immunostimulatory effects in the extracellular space, which are referred to as damage-associated molecular patterns (DAMPs). [2] [3] [4] [5] Tubular damage also induces Tamm-Horsfall protein (THP)/uromodulin leakage from the tubular lumen into the interstitium, where it turns into an immunostimulatory danger signal. 6, 7 DAMPs activate a set of pattern recognition receptors, such as Toll-like receptors (TLRs) or inflammasomes, on renal parenchymal cells as well as in interstitial dendritic cells. [2] [3] [4] [5] [6] [7] [8] [9] The subsequent innate immune response involves the transcription of numerous proinflammatory cytokines and chemokines, which initiate the influx of various immune cell subsets into the kidney, that contribute to the early amplification of the inflammatory response and AKI by enhancing immune-mediated tubular cell death. 10, 11 To limit overshooting immunopathology in sterile tissue injuries and allow tissue recovery, 12 a number of counterregulatory mechanisms exists that mostly limits immune activation of intrarenal dendritic cells. 13, 14 For example, pentraxin-3 release from the microvasculature and dendritic cells limits leukocyte recruitment. 15, 16 Most importantly, switching the phenotype of intrarenal mononuclear phagocytes away from classically activated (proinflammatory) to alternatively activated (anti-inflammatory/proregeneratory) cells is necessary for recovery on AKI. [17] [18] [19] Although surviving tubular epithelial cells (TECs) enter the cell cycle within few hours on injury, 1 a functional tubular recovery does not occur before the resolution of sterile inflammation has occurred and the tubulointerstitial microenvironments become dominated by proregeneratory factors. 18, 19 They are provided in a paracrine manner by other surviving TECs, intratubular tubular progenitor cells, or bone marrow-derived stem cells. 1, [20] [21] [22] [23] Although dendritic cells and other immune cells play a dominant role in orchestrating the early injury phase of AKI, little is known about the contribution of intrarenal immune cells to the subsequent phase of kidney regeneration. 24 Three reports recently consistently showed that mononuclear phagocyte depletion in the healing phase of postischemic AKI impairs tubular regeneration, 18, 19, 25 but the phagocyte-derived mediators that drive tubular healing remain unknown. Zhang et al. 19 showed that colony-stimulating factor (CSF)-1 activates M2 macrophage-dependent tubular repair, but CSF-1 is predominately produced by activated tubular cells. 26 M2 macrophages produce IL-10 and growth factors like TGF-b that have anti-inflammatory and profibrotic effects, but more specific myeloid cell-derived mediators that enhance epithelial healing should exist.
Generally, we follow the concept that renal mononuclear phagocytes orchestrate all phases of AKI-the onset and the resolution of inflammation as well as subsequent tissue regeneration or repair. 27 Here, we focused on the ILs, a paradigmatic family of leukocyte-derived mediators that regulates homeostasis and immunity in a paracrine manner. We hoped to identify yet unknown proregeneratory properties of ILs on TEC regeneration in AKI. Our unbiased in vitro screening approach revealed IL-22 as a candidate, which we subsequently validated as a renal dendritic cell-derived stimulator of tubular regeneration. To our surprise, we found IL-22 secretion to be selectively induced by TLR4 agonists released from necrotic tubular cells, which first documents a role of TLR signaling for not only renal immunopathology but also, kidney regeneration in vivo. Furthermore, our data imply that dying TECs involve interstitial dendritic cells to support their regeneration through a specific TLR4-IL-22 pathway.
RESULTS

IL-22 Enhances Tubular Cell Re-Epithelialization by
Jak-Stat3 and Erk1/2 In Vitro First, we set up an experimental system that mimics primary tubular cell recovery on ischemia-reperfusion injury. We used kidney explanation from adult mice and the preparation of renal tubular cell suspensions for culture as a model of ischemia-reperfusion injury, in which, similar to severe AKI, less than 10% of the TECs survived. 19, 28 We considered the regenerative outgrowth from the surviving TECs reforming a monolayer as a valuable in vitro system to screen for the impact of ILs on post-ischemic epithelial healing. Among all ILs tested, recombinant IL-22 had the strongest proregeneratory effect ( Figure 1A ). To better mimic epithelial monolayer injury and validate this candidate, we also tested IL-22 on mechanical scratching of primary TEC monolayers. Recombinant IL-22 dose dependently enhanced wound closure ( Figure 1B) , confirming that IL-22 enhances re-epithelialization on TEC injury. Which signaling pathways contribute to this process? Recombinant IL-22 induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) and extracellular signalregulated kinases 1/2 (ERK1/2) in primary TECs, a process that was blocked by an mitogen-activated protein kinase (MEK1/2) inhibitor ( Figure 1C ). Furthermore, Jak1 and MEK1/2 inhibition partially abrogated the proregeneratory effect of recombinant IL-22 on mechanical scratch-induced epithelial injury of primary TEC monolayers ( Figure 1D ). The inhibitors did not affect the wound healing process on their own. Thus, IL-22 enhances re-epithelialization on TEC injury through activation of the Jak/STAT3P and ERK1/2 pathways.
Neutralizing Endogenous IL-22 Impairs Epithelial Recovery on AKI
To confirm the role of IL-22 on epithelial repair in vivo, we first characterized the expression of IL-22 in plasma (ELISA) and kidney (RT-PCR) 1, 5, and 10 days after unilateral renal pedicle clamping. Plasma IL-22 protein levels were significantly elevated at days 5 and 10 (Supplemental Figure 1A) , whereas intrarenal IL-22 mRNA levels increased as early as day 1 (Figure 2A) . IL-22 immunostaining revealed positivity exclusively in the interstitial compartment on day 1 as well as day 5 in post-ischemic but not contralateral control kidneys after unilateral renal pedicle clamping ( Figure 2B ). By contrast, IL-22R immunostaining displayed positivity exclusively in TECs (Figure 2C) . We also found extrarenal expression of IL-22 in postischemic injury (e.g., in splenic dendritic cells) ( Figure 2D ).
To investigate the functional significance of endogenous IL-22 for AKI recovery, we neutralized IL-22 in the healing phase of AKI by injecting anti-IL-22 antibody only from day 2 after renal pedicle clamping and euthanized the mice on day 5. This time point was selected, because in our model, the injury phase lasts for 48 hours; the recovery phase covers days 2-5 at the given ischemia time. 29 IL-22 blockade significantly impaired tubular recovery as defined by the index of injured tubules assessed on periodic acid-Schiff sections, the numbers of Lotus tetragonolobus lectin + proximal tubules and THP + distal tubules, and the number of proliferating THP + proliferating cell nuclear antigen + cells ( Figure 3 ). IL-22 neutralization did not affect IL-22 expression as assessed by IL-22 staining ( Figure 3A ). This result was consistent with the profound increase in the renal mRNA expression levels of the tubular injury markers kidney injury molecule (Kim)-1, p2glutathione S-transferase (GST), a-GST, and fatty acid-binding protein (FABP) versus isotype controls (Figure 3B) . To understand the role of IL-22 in regaining renal function after ischemic tubular injury, we carried out bilateral ischemic injury in Il-22-deficient mice. These mice displayed impaired tubular regeneration accompanied by higher plasma BUN levels on day 5 ( Figure  3C ). Of note, plasma BUN levels were identical at day 1, implying that IL-22 does not contribute to the injury phase of AKI. Together, the post-ischemic kidney induces IL-22 expression, which supports tubular recovery during the healing phase of AKI. Figure 2 ). Immunostaining confirmed the depletion of IL-22-producing leukocytes in the post-ischemic kidney at day 5 ( Figure 4B ). Clodronate-induced depletion of mononuclear phagocytes was recently reported to impair tubular repair in this model. 18, 19, 25 Our own experiments reproduced the phenotype of impaired AKI recovery reported by these studies, because clodronate depletion of renal mononuclear phagocytes reduced the proliferating cell nuclear antigen tubules ( Figure 5A ), showing insufficient tubular cell proliferation as a cause for poor AKI recovery, which was evidenced by a higher tubular necrosis index and elevated tubule injury marker (Kim-1, p-GST, a-GST, and FABP) mRNA expression at day 5 ( Figure 5B ). However, does this effect specifically relate to a lack of IL-22 release by the depleted mononuclear phagocytes?
Interstitial
To address this question, we injected recombinant IL-22 from day 3 into clodronate liposome-treated mice. IL-22 reconstitution recovered tubular cell repair, which was indicated by normalization of all the aforementioned AKI parameters ( Figure 5 , A and B). We examined the effect of renal phagocytes depletion on renal function in post-ischemic injury. Renal phagocyte depletion impaired tubular recovery, which was indicated by elevated plasma BUN on day 5. Reconstitution of IL-22 normalized plasma BUN ( Figure 5C ). These findings show that renal mononuclear phagocytes contribute to AKI recovery during the healing phase by secreting IL-22. Figure 6B ). To further confirm the role of TLR4, we blocked the necrotic supernatant stimulation with a neutralizing TLR4 antibody, which entirely suppressed IL-22 release in a dose-dependent manner ( Figure 6C ). Necrotic supernatant and TLR4 stimulation of primary renal dendritic cells also induced IL-22 expression ( Figure 6D ). In contrast, direct TLR4 stimulation of TEC monocultures did not affect their viability or growth (Supplemental Figure 4 , B and C). These data document that necrotic TECs trigger IL-22 release in dendritic cells by TLR4 activation.
TLR4 Activation-Mediated IL-22 Release Drives Tubular Repair on Post-ischemic AKI TLR4 activation triggers innate immunity, immunopathology, and the extent of AKI during the early injury phase of AKI. 30 To test a putative role of TLR4 in AKI recovery experimentally requires either a conditional knockout approach or a specific TLR4 antagonist. Because conditional TLR4 2/2 mice are not available, we used a TLR4 blocking antibody. However, when we injected anti-TLR4 IgG only from 48 hours after renal pedicle clamping, it partially reduced intrarenal expression of IL-22, which was evidenced by decreased expression of IL-22 in the injured kidney ( Figure 7A ). In this way, TLR4 inhibition impaired tubular recovery on post-ischemic AKI, which was illustrated by an increased index of tubular necrosis, lower numbers of lectin + or THP + tubules, and the tubular injury marker p-GST ( Figure 7B ). TLR4 blockade with CLI-095 initiated in the recovery phase was also associated with higher BUN levels on bilateral ischemic injury (P=0.06), which indicates that TLR4 blockade during recovery phase slows down the process of the tubular repair, whereas TLR4 blockade during the injury phase prevented AKI ( Figure 7C ). Together, releases from necrotic TECs activate TLR4 on intrarenal mononuclear phagocytes to induce IL-22, a mechanism that enhances tubular recovery during the healing phase of AKI.
DISCUSSION
We had hypothesized that some ILs may hold the potential to drive tubular regeneration during the recovery phase of AKI. IL-22 is a member of the IL-10 family of cytokines with regulatory roles in tissue repair. 33 IL-22 regulates the proliferation of keratinocytes in psoriasis, 34, 35 lung epithelial cells in lung injury, 36 enterocytes on toxic mucosal injury, 37, 38 hepatocytes in liver injury, 39, 40 and thymic epithelial cells on total body irradiation. 41 The data from epithelial organs, like the gut and the skin, are consistent with our findings, documenting the conceptual similarities between re-epithelialization of TEC monolayer injury inside renal tubules and re-epithelialization of epithelial surfaces in other body compartments. IL-22-mediated re-epithelialization involves binding to its receptor IL-22R on TECs followed by activation of STAT3 and ERK1/2 phosphorylation. 42 Although T and NKT cells were first thought to represent the predominant IL-22-producing cells, 43, 44 IL-22 secretion by dendritic cells has previously been recognized. 38, 45 The dense network of interstitial dendritic cells in the healthy kidney seems to be the first source of intrarenal IL-22 secretion. 46 Three studies as well as our own results showed an unexpected contribution of renal mononuclear phagocytes to AKI recovery by depleting them with clodronate selectively during the recovery phase. This process depleted the IL-22-producing cells, although it is theoretically possible that clodronate indirectly reduced IL-22 production. 18, 19, 25 IL-22 reconstitution recovered this phenotype, which identifies IL-22 as a paracrine mediator of this effect. It remains unclear if IL-22 reconstitution also had a supraphysiological therapeutic effect. It is likely that IL-22 is just one of several phagocyte-derived factors that regulate the healing process. However, these data add on to the existing evidence that the various phenotypes of intrarenal dendritic cells and macrophages orchestrate all phases of tissue injury and recovery to allow tissues to regain and maintain homeostasis. 24 We also identified TLR4 signaling as a stimulus for IL-22 secretion in dendritic cells, similar to the endogenous DAMP concept of cell necrosis-induced activation of sterile inflammation. 47 This finding does not contradict the proinflammatory role of TLR4 in the injury phase of AKI. In fact, rapid repair of epithelial barriers is another important innate response mechanism of pathogen control and host defense (e.g., inside the intestinal epithelium or the skin), which implies that inflammation and rapid re-epithelialization are both needed and potentially triggered by the same signaling cascades during host defense. The potential of the TLR/MyD88 53 Altogether, IL-22 is a previously unknown mediator of TEC regeneration during the AKI recovery phase. TEC necrosis provides a stimulus to TLR4-mediated induction of IL-22 secretion by intrarenal dendritic cells and other mononuclear phagocytes. The mitogenic effects of IL-22 on the surviving TECs are mediated by IL-22R and subsequent STAT3 and ERK1/2 phosphorylation. We conclude that TLR4 signaling drives epithelial regeneration on post-ischemic AKI through secretion of IL-22 from mononuclear phagocytes, which links the two danger response programs of renal inflammation and regeneration at the level of TLR4.
CONCISE METHODS
Isolation of Tubular Epithelial Cells
We performed complete perfusion with sterile Dulbecco's phosphate-buffered saline (DPBS) on 6-to 7-week-old wild-type C57BL6 mice by puncture of the left ventricle. Subsequently, both kidneys were weighed, mashed, digested in collagenase (Collagenase A; Roche Diagnostics) for 30 minutes, and then sieved through a 70-mm sieve. After one step of centrifugation (1500 rpm for 5 minutes), the tubular fragments were resuspended in 2 ml DPBS, carefully layered on a 31% Percoll column, and centrifuged (3000 rpm for 10 minutes). The pellet (tubular fragments) was washed two times in DPBS and then cultured in hormone-conditioned media at 37°C and 5% CO 2 as described. 28 
Assessment of Regeneration
We performed a large-scale screening experiment with over 20 cytokines (Immunotools). Right after isolation, an equal amount (according to the kidney weight) of tubular fragments was plated into 24-well plates. On the same 24-well plates, four squares (434 mm) with a gap between them were marked on the bottom of the plate before the cell culture. Photos of these squares were taken with a phase contrast microscope (ProgRes software; Leica) on day 5 after ischemia. By digital analysis (Photoshop; Adobe), the area surface covered by tubular cells was measured in percent to the total image size.
Scratch Assay
For scratch assays, artificial wounds were created through standardized scratching of the tubular cell monolayer with a pipette tip. IL-22 was added to the cells at different concentrations (0.1, 1, and 10 ng/ml). Two pictures per wound were taken on a phase contrast microscope at different time points (0, 16, 20, and 24 hours). Changes in wound size were analyzed digitally (Photoshop) and then translated into wound closure. To understand the functional role of various pathways, scratch assay was performed in the presence of JAK-STAT inhibitor (10 nM Jak inhibitor I; Santa Cruz Biotechnology) and MEK1/2 inhibitor (10 mM PD98059; Cell Signaling Technology), and cells were stimulated with 1 ng/ml IL-22.
Protein Isolation and Western Blotting
We extracted protein from cell lysate using RIPA buffer (Sigma-Aldrich) containing protease inhibitors (Roche Diagnostics) and phosphatase inhibitor (Sigma-Aldrich) and processed it for Western blotting as described. 29, 54 Briefly, proteins were separated by SDS-PAGE and then transferred to a polyvinylidene difluoride membrane. Nonspecific binding to the membrane was blocked for 2 hours at room temperature with 5% BSA in Tris-buffered saline buffer. The membranes were incubated overnight at 4°C with primary rabbit antibodies against mouse p-stat3, p-ERK 42/44, and b-actin (Cell Signaling Technology). After washing, the membranes were incubated with peroxidase-conjugated secondary antibodies in Tris-buffered saline buffer. Secondary antibodies were peroxidase-conjugated anti-rabbit IgG (Cell Signaling Technology). The signals were visualized by an enhanced chemiluminescence system (Amersham).
BMDC Stimulation Experiments
BMDCs were generated by established protocols. Briefly, bone marrow cells were harvested from mouse femor and cultured with granulocyte macrophage CSF (2 ng/ml) for 8 days. Cell media were replaced on day 8, and adherent dendritic cells were stimulated. Renal dendritic cells were isolated from whole kidneys by magnetic bead separation (MACS) using CD11c MicroBeads (Miltenyi Biotech). The purity of CD11c + renal cells was confirmed by FACS analysis using antiCD11c antibody (BD Biosciences-Pharmingen). Necrotic cell supernatants were prepared from mouse tubular cells by repeated freezing and thawing. BMDCs were stimulated with necrotic supernatant with different concentration (50, 150 , and 250 ml) as well as AhR agonist (FICZ; Enzo Life Sciences) and H 2 O 2 (Merck). We purchased ultrapure LPS (from Escherichia coli strain K12), pI:C RNA, Pam3Cys, imiquimod, and CpG (InvivoGen). All cells were stimulated in serum-free RPMI 1640 medium (Invitrogen) at a density of 1310 6 cells/ml. Cells were stimulated for 16 hours with LPS (1 mg/ml), pI:C RNA (5 mg/ml), Pam3Cys (1 mg/ml), imiquimod (1 mg/ml), and CpG (3 mg/ml). Cell Animal Experiments C57BL/6 wild-type mice were obtained from Charles River (Sulzfeld, Germany). Il-22-deficient mice were provided by S. Kobold. Mice were housed in groups of five in filter-top cages with unlimited access to food and water. Cages, food, and water were sterilized by autoclaving before use. Unilateral (45 minutes) and bilateral (25 minutes) renal ischemia-reperfusion injuries were induced under general anesthesia as previously described. 29 Mice were euthanized 1 and 5 days later, and pieces from ischemic and contralateral (sham) kidneys were snapfrozen in liquid nitrogen and fixed in 10% buffered formalin. In some experiments, mice received intraperitoneal injections with either 20 mg/ injection of the anti-IL-22 antibody or isotype control (eBiosciences) on days 2, 3, and 4 postinjury. Clodronate-liposome and PBS-liposome (200 ml per mouse per injection), both of which were procured from Haarlem (The Netherlands), were injected on days 1, 2, and 4 postinduction of injury. Recombinant IL-22 (20 mg/ mouse; Biolegend) was injected in clodronateliposome-injected mice on day 3 post-ischemic injury. Anti-TLR4 antibody (15 mg per mouse per injection; Biolegend) and isotype control were injected as specified. TLR4 inhibitor (CLI-095; Invivogen) was injected at the dose of 1 mg/kg on day 0 (pre) as well as days 2, 3, and 4 post-ischemic injury. Plasma BUN was determined by taking blood samples on days 0, 1, and 5. IL-22 knockout mice were also examined to understand the role of IL-22 on renal function. All experiments were conducted according to German animal protection laws (equivalent to the National Institutes of Health Guide for the Care and Use of Laboratory Animals) and had been approved by the local government authorities.
Assessment of Kidney Inflammation and Injury
Kidneys were embedded in paraffin, and 2-mm sections were used for periodic acid-Schiff stains and immunostaining as described. 55 Post-ischemic tubular injury was scored by assessing the percentage of tubules in the corticomedullary junction that displayed tubular cell flattening, cell necrosis, loss of brush border, and luminal cast formation as 0, none; 1, #10%; 2, 11%-25%; 3, 26%-45%; 4, 46%-75%; 5, .76%. For histochemistry, we used biotinylated L. tetragonolobus lectin stain (Vector Labs), THP stain (Santa Cruz Biotechnology), proliferating cell nuclear antigen (Cell Signaling Technology), IL-22R (BIOSS), and IL-22 antibody (Santa Cruz Biotechnology). To quantify the IL-22 staining, the slides were scanned using an Olympus BX 61 microscope and recorded with CellP software. The scans underwent digital stain counting using Adobe Photoshop.
Real-Time Quantitative RT-PCR
Total RNA was isolated from kidneys using a Qiagen RNA extraction kit following the manufacturer's instructions. After quantification, RNA quality was assessed using agarose gels. From isolated RNA, cDNA was prepared using reverse transcription (Superscript II; Invitrogen). Real-time quantitative RT-PCR was performed using SYBRGreen PCR master mix and analyzed with a Light Cycler 480 (Roche Diagnostics). All gene expression values were normalized using 18s RNA as a housekeeping gene, and negative controls were used for quality control as described. 56 All primers used for amplification were from Metabion and are listed in Table 2 .
Flow Cytometry
Anti-mouse CD11c, CD11b, CD103, F4/80, and CD45 antibodies (BD Biosciences-Pharmingen) were used to detect renal mononuclear phagocyte populations in the ischemic kidneys as described 57 ; 7/4 (Abd Serotec), Ly6G (BD), CD3 (BD), and NK1.1 (BD) antibodies were used to detect neutrophil, T cell, and NK cell in the ischemic kidneys. IL-22 expression was determined using intracellular staining with IL-22 antibodies (R&D Systems). Respective isotype antibodies were used to show specific staining of cell populations. Quantification of cell number was achieved using counting beads (Invitrogen).
Statistical Analyses
Data are presented as mean6SEM. Comparison of groups was performed using ANOVA or t test; post hoc Bonferroni correction was used for multiple comparisons. A P value ,0.05 were considered significant. 
